Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations

Oncotarget

Volumn 7, Issue 8, 2016, Pages 9404-9419

  Sun, Yi ^a   Zhang, Wei ^a   Chen, Yunqin ^b   Ma, Qin ^c   Wei, Jia ^b   Liu, Qi ^a  

^a TONGJI UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Cancer cell line; Drug resistance; Drug response; Drug sensitivity; Personalized treatment

Indexed keywords

CALVASCULIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ABCB1 GENE; ABCC1 GENE; ARTICLE; BLVRB GENE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL COMMUNICATION; COMPUTER MODEL; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; EGFR GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; H19 GENE; HUMAN; HUMAN CELL; ID4 GENE; IGFBP3 GENE; IN VITRO STUDY; LETHALITY; MGST1 GENE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRMT6 GENE; PTEN GENE; S100A4 GENE; S100P GENE; SLC26A2 GENE; SOSTDC1 GENE; TNC GENE; TOP2A GENE; TRANSCRIPTOMICS; ALGORITHM; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENETIC VARIATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY; SKIN NEOPLASMS; THEORETICAL MODEL; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; MODELS, THEORETICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SKIN NEOPLASMS;

EID: 84961626619     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7012     Document Type: Article

References (59)

1. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012; 109:2724-2729
2. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4:2126
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-607
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483:570-575
5. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013; 41:D955-961
6. Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-Ud-Din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014; 32:1202-1212
7. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, et al. Modeling precision treatment of breast cancer. Genome Biol. 2013; 14:R110
8. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014; 15:R47
9. Masica DL, Karchin R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res. 2013; 73:1699-1708
10. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9:665-674
11. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521:489-494
12. Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-thescience. Expert Rev Anticancer Ther. 2012; 12:1571-1577
13. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6:813-823
14. Center. WotHL. http://lincs.hms.harvard.edu/niepelbmcbiol-2014/
15. Chaignat E, Yahya-Graison EA, Henrichsen CN, Chrast J, Schutz F, Pradervand S, Reymond A. Copy number variation modifies expression time courses. Genome Res. 2011; 21:106-113
16. Orozco LD, Cokus SJ, Ghazalpour A, Ingram-Drake L, Wang S, van Nas A, Che N, Araujo JA, Pellegrini M, Lusis AJ. Copy number variation influences gene expression and metabolic traits in mice. Hum Mol Genet. 2009; 18: 4118-4129
17. Cahan P, Li Y, Izumi M, Graubert TA. The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nat Genet. 2009; 41:430-437
18. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007; 315:848-853
19. Lu TP, Lai LC, Tsai MH, Chen PC, Hsu CP, Lee JM, Hsiao CK, Chuang EY. Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS One. 2011; 6:e24829
20. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012; 338:221
21. Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Nextgeneration sequencing of paired tyrosine kinase inhibitorsensitive and-resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 2013; 23:1434-1445
22. Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003; 22:7262-7264
23. Soundararajan V, Aravamudan M. Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy. Scientific reports. 2014; 4:7294
24. Vuong H, Cheng F, Lin CC, Zhao Z. Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome medicine. 2014; 6:81
25. Barranco M, Martínez L. A Method for Weighting Multivalued Features in Content-Based Filtering. In: García-Pedrajas N, Herrera F, Fyfe C, Benítez J, Ali M, eds. Trends in Applied Intelligent Systems: Springer Berlin Heidelberg, 2010; 409-418
26. C.-C. Chang C-JL. LIBSVM: a library for support vector machines. ACM Transactions on Intelligent Systems and Technology. 2011; 2:27:21-27:27
27. Kolev M, Towner L, Donev R. Complement in cancer and cancer immunotherapy. Archivum immunologiae et therapiae experimentalis. 2011; 59:407-419
28. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nature immunology. 2008; 9:1225-1235
29. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood. 2004; 104:2746-2751
30. Maia AT, Spiteri I, Lee AJ, O'Reilly M, Jones L, Caldas C, Ponder BA. Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. Breast cancer research: BCR. 2009; 11:R88
31. Jerby-Arnon L, Pfetzer N, Waldman YY, McGarry L, James D, Shanks E, Seashore-Ludlow B, Weinstock A, Geiger T, Clemons PA, Gottlieb E, Ruppin E. Predicting cancerspecific vulnerability via data-driven detection of synthetic lethality. Cell. 2014; 158:1199-1209
32. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008; 118:2609-2619
33. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362:362-369
34. Zhang F, Zhang T, Qu Y, Jiang T, Cao YX, Li C, Fan L, Mei QB. Replication-dependent gamma-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010; 24:1297-1305
35. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28:1145-1153
36. Peterson-Roth E, Brdlik CM, Glazer PM. Src-Induced cisplatin resistance mediated by cell-to-cell communication. Cancer Res. 2009; 69:3619-3624
37. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22:7265-7279
38. Fontemaggi G, Dell'Orso S, Muti P, Blandino G, Strano S. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell cycle. 2010; 9:2464-2466
39. Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G. ID4: a new player in the cancer arena. Oncotarget. 2010; 1:48-58. doi: 10.18632/oncotarget.108
40. Tan BS, Tiong KH, Choo HL, Fei-Lei Chung F, Hii LW, Tan SH, Yap IK, Pani S, Khor NT, Wong SF, Rosli R, Cheong SK, Leong CO. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKTdependent suppression of BCL2-modifying factor (BMF). Cell death & disease. 2015; 6:e1826
41. Alvarez Secord A, Bernardini MQ, Broadwater G, Grace LA, Huang Z, Baba T, Kondoh E, Sfakianos G, Havrilesky LJ, Murphy SK. TP53 Status is Associated with Thrombospondin1 Expression In vitro. Frontiers in oncology. 2013; 3:269
42. Hafizi S, Ibraimi F, Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB journal. 2005; 19:971-973
43. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. British journal of cancer. 2003; 88:1285-1291
44. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2011; 21:440-446
45. AbuHammad S, Zihlif M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 2013; 101:213-220
46. Mencia N, Selga E, Rico I, de Almagro MC, Villalobos X, Ramirez S, Adan J, Hernandez JL, Noe V, Ciudad CJ. Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC cancer. 2010; 10:250
47. Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicinresistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anti-cancer drugs. 1998; 9:311-317
48. Zeng X, Morgenstern R, Nystrom AM. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. Biomaterials. 2014; 35:1227-1239
49. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Journal of the National Cancer Institute. 2007; 99:1107-1119
50. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007; 26:4877-4881
51. Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene. 2015; 34:726-740
52. Dowhan DH, Harrison MJ, Eriksson NA, Bailey P, Pearen MA, Fuller PJ, Funder JW, Simpson ER, Leedman PJ, Tilley WD, Brown MA, Clarke CL, Muscat GE. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrine-related cancer. 2012; 19:509-526
53. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003; 94:15-21
54. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13:714-726
55. Jaccard P. Distribution de la Flore Alpine: dans le Bassin des dranses et dans quelques régions voisines. Rouge (1901)
56. Tanimoto TT. IBM internal report. Nov. 1957; 17:1957
57. Jun Liu, Shuiwang Ji, Ye J. SLEP: Sparse Learning with Efficient Projections Arizona State University. 2009
58. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009; 4:44-57
59. Li G, Ma Q, Tang H, Paterson AH, Xu Y. QUBIC: a qualitative biclustering algorithm for analyses of gene expression data. Nucleic Acids Res. 2009; 37:e101